Invus Public Equities, L.P.
CIK 1340097 · last filed 2024-12-12
Invus Public Equities, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider sold $333.2M of SRRK on Dec 12, 2024. Across all open-market trades the lifetime net is −$307.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $438.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$438.16M
3
9
-$307.87M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SRRK | 10%+ Owner | 9,700,005 | $44.18 | $428.55M | -$160.57M | 5 | 2024-12-12 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 6,695,658 | $15.70 | $105.12M | -$1.49M | 3 | 2024-08-07 |
| SEER | 10%+ Owner | 5,588,366 | $1.72 | $9.61M | -$145.81M | 1 | 2021-02-03 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-12 | SRRK | Sell (S) | −8,000,000 | -$333.20M | EDGAR |
| 2024-08-07 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Sell (S) | −1,101,275 | -$205.9K | EDGAR |
| 2024-07-30 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Sell (S) | −6,895,595 | -$1.58M | EDGAR |
| 2023-10-16 | SRRK | Buy (P) | +17,599,448 | $120.69M | EDGAR |
| 2023-05-02 | SRRK | Buy (P) | +252,456 | $1.62M | EDGAR |
| 2023-02-13 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +91,608 | $297.0K | EDGAR |
| 2023-01-11 | SRRK | Sell (S) | −8,752 | -$83.0K | EDGAR |
| 2021-02-03 | SEER | Sell (S) | −2,272,905 | -$145.81M | EDGAR |
| 2018-05-31 | SRRK | Mixed | +19,168,320 | $50.40M | EDGAR |